Search clinical trials for: Losmapimod matched Placebo

Total 54262 results

GlaxoSmithKline

Completed

Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Germany, Estonia, Ukraine, Korea, Republic of, Norway, Czechia
GlaxoSmithKline

Completed

PK Study of IV Formulation of GW856553

Cardiovascular Disease

United Kingdom
GlaxoSmithKline

Completed

A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging

Atherosclerosis

United Kingdom
Fulcrum Therapeutics

Completed

Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) (FSHD)

Facioscapulohumeral Muscular Dystrophy (FSHD)

United States, Canada, France, Spain
Cambridge University Hospitals NHS Foundation Trust
GlaxoSmithKline; University of Cambridge; Royal Brompton & Harefield NHS Foundation... and other collaborators

Completed

Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen. (EVOLUTION)

Chronic Obstructive Pulmonary Disease

United Kingdom
Fulcrum Therapeutics

Terminated

Losmapimod Safety and Efficacy in COVID-19 (LOSVID)

COVID-19

United States, Mexico, Brazil, Peru
GlaxoSmithKline

Completed

Phase I Study of GW856553 (Losmapimod)

Acute Coronary Syndrome

Australia
Fulcrum Therapeutics

Completed

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

Healthy Adult Subjects

United States
Fulcrum Therapeutics

Active, not recruiting

Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension (FSHD)

Facioscapulohumeral Muscular Dystrophy 1

Netherlands
Fulcrum Therapeutics

Active, not recruiting

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

Facioscapulohumeral Muscular Dystrophy (FSHD)

United States, Canada, France, Spain
Cedars-Sinai Medical Center

Completed

Personalized Cancer Care at Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute

Cancer

United States
Fulcrum Therapeutics

Active, not recruiting

Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

Facioscapulohumeral Muscular Dystrophy (FSHD)

United States, Spain, Italy, Denmark, Canada, Germany, France, Netherlands, United Kingdom
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin

Acute Coronary Syndrome

United States
Gateway Institute for Brain Research

Recruiting

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease (NOSE-PD)

Parkinson Disease

United States
GlaxoSmithKline

Completed

A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)

Glomerulosclerosis, Focal Segmental

United States, Canada
Ore Pharmaceuticals, Inc.

Unknown

Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis

Mild to Moderate Ulcerative Colitis

Canada, India
GlaxoSmithKline

Completed

Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy

Muscular Dystrophies

Germany, Belgium, Turkey, Netherlands, Spain, Israel, Australia, France, United Kingdom
Montefiore Medical Center
United States Department of Defense; Jazz Pharmaceuticals

Recruiting

Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)

Autism Spectrum Disorder

United States
Pfizer

Terminated

A Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers

Sleep | Healthy Volunteers

United States
Takeda

Terminated

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants

Pharmacokinetics | Pharmacodynamics | Tolerability | Safety

United States
E-Star BioTech, LLC
Mayo Clinic; PPD

Not yet recruiting

To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

Difficult to Control Hypertension
Eisai Inc.

Completed

A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants

Healthy Volunteers

United States
Eisai Inc.

Completed

A Study to Assess the Safety and Tolerability of E2730 After Multiple Dose and the Food Effect After Single Dose in Healthy Participants

Healthy Volunteers

United States
Eisai Inc.

Completed

A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants

Healthy Volunteers

United States
Pfizer

Completed

Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers

Healthy | Sleep

United States
Eisai Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects

Healthy Subjects

United States
Bristol-Myers Squibb

Completed

To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants

Thrombosis

United States
Moleac Pte Ltd.

Completed

Study of NeuroAid In Enhancing Recovery After Stroke (TIERS)

Stroke | Cerebral Infarction

Singapore
Florida State University

Completed

Nighttime Feeding and Morning Endurance Performance

Poor Performance Status

United States
Ipsen

Recruiting

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (ELFIDENCE)

Primary Biliary Cholangitis (PBC)

United States, Spain, France, Korea, Republic of, Italy, Czechia, Poland, Romania
EMD Serono
Merck KGaA, Darmstadt, Germany

Terminated

Atacicept in Subjects With Optic Neuritis

Optic Neuritis

United States, France, Spain, United Kingdom, Canada, Germany, Czech Republic, Belgium, Australia, Switzerland, Lebanon
Navitor Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc.

Recruiting

Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

Treatment Resistant Depression

United States
Destiny Pharma Plc

Completed

Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection

Staphylococcal Infections | Surgical Site Infection

United States, Serbia, Georgia
National University Hospital, Singapore

Completed

NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented Subjects (NEURITES)

Cognitive Impairment

Singapore, Philippines, Vietnam
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I) (AUGUST I)

Rheumatoid Arthritis

United States, Canada
GlaxoSmithKline
The TIMI Study Group

Completed

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60) (LATITUDE)

Acute Coronary Syndrome

United States, Australia, France, Spain, Taiwan, Estonia, Poland, Russian Federation, Belgium, Philippines, Sweden, Thailand, Germany, Israel, Bulgaria, Hong Kong, Netherlands, Norway, Slovakia, South Africa, Korea, Republic of, R... and more
Agios Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

Healthy Volunteers | Anemia, Sickle Cell

United States, Spain, Denmark
Sprim Advanced Life Sciences
Cerebos

Completed

Effects of Essence of Chicken on Physical Fatigue, Working Memory and Attention

Fatigue | Healthy Subjects
Indiana University School of Medicine

Completed

A Pilot Study of Fish Oil Supplementation in Hemodialysis Patients

End-Stage Renal Disease Patients on Hemodialysis

United States
GlaxoSmithKline

Completed

GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults

Sepsis

United States, Canada, France, Netherlands, Russian Federation, Taiwan, Czechia, Estonia, Spain, Sweden, Thailand, Germany, Belgium, Israel, United Kingdom, Korea, Republic of, Portugal, Finland, Latvia, New Zealand, Malaysia, South... and more
Ipsen

Recruiting

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. (ELMWOOD)

Primary Sclerosing Cholangitis

United States, Spain, Germany, Canada, United Kingdom, Italy, Portugal
University of Virginia
National Institutes of Health (NIH)

Completed

Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication

Peripheral Arterial Disease | Intermittent Claudication

United States
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis (FENtrepid)

Multiple Sclerosis, Primary Progressive

United States, Canada, Australia, United Kingdom, Hungary, Bulgaria, Puerto Rico, Poland, Argentina, Brazil, Germany, Greece, Italy, Peru, Portugal, Russian Federation, Spain, Turkey, Ukraine, Israel, France, Switzerland, Colombia, Me... and more
Wuhan Createrna Science and Technology Co., Ltd

Completed

A Study of Multiple Ascending Doses MY008211A in Healthy Adults

Paroxysmal Nocturnal Hemoglobinuria

China
Eisai Co., Ltd.

Completed

A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout

Gout

China
Hansoh BioMedical R&D Company

Recruiting

Study of HS-10384 in Participants of Chinese Postmenopausal Women

Vasomotor Symptoms

China
Taisho Pharmaceutical Co., Ltd.

Completed

A Clinical Pharmacology Study of TS-142 in Patients With Obstructive Sleep Apnea Hypopnea.

Patients With Mild Obstructive Sleep Apnea Hypopnea

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

Early Phase 2 Clinical Study of TS-142 in Patients With Insomnia Disorder

Insomnia Disorder

Japan
Merck Sharp & Dohme LLC

Completed

Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)

Primary Insomnia
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

Psoriasis

China

Search clinical trials for: Losmapimod matched Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations